ArticleScientific reports2026
Daily biomarker trajectories predict major bleeding in patients on venovenous ECMO for ARDS: a retrospective longitudinal cohort study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bleeding complications during venovenous extracorporeal membrane oxygenation (ECMO) remain a leading cause of morbidity, yet granular longitudinal data linking daily biomarker dynamics to bleeding around circuit exchanges are scarce. We analyzed 93 exchanges from 35 severe acute respiratory distress syndrome (ARDS) patients (2020–2022) across 15-day peri-exchange windows in this retrospective single-center cohort study. Major bleeding (defined by ELSO criteria) occurred on 100/1317 observation-days (7.6%), clustering peri-exchange (13.1% vs. 4.2% outside ± 2 days, p < 0.001). Using generalized linear mixed models (GLMMs) with nested random effects, we characterized coagulation trajectories and bleeding predictors. White blood cell count was the strongest predictor (OR 2.00/SD, 95% CI 1.43–2.82, p < 0.001), followed by platelets (OR 0.58, p = 0.014) and fibrinogen (OR 0.60, p = 0.035). Time-lagged GLMMs identified D-dimer and fibrinogen as early warning markers 1–2 days pre-bleeding. Circuit exchange shortened bleeding duration (HR 2.23, 95% CI 1.16–4.29, p = 0.017). D-dimer rose pre-exchange and declined post-exchange, while fibrinogen and platelets showed inverse patterns, suggesting consumptive coagulopathy reversed by exchange. White blood cell trajectories implicated independent inflammatory risk. These findings demonstrate a 1–2 days predictive time window for any action needed to counteract or prevent major bleeding, supporting biomarker-guided circuit management and hemostatic strategies in ECMO.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.